Vistagen Therapeutics, Inc. (VTGN)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.17
- As of
Kresmion compiles this page from VTGN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Vistagen Therapeutics, Inc. (VTGN): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-09.
See the full VTGN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VTGN on one page. Preview it with sample data, then open it live with a free account.
Preview the VTGN dossierActive events for VTGN
- mediumEarnings above estimates
Q1-2027: Beat consensus by 20.5%, EPS $-0.30 vs $-0.3774 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 97% of VTGN (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 85% of VTGN (2026Q2)
- high13F: large reduction
CITADEL ADVISORS LLC cut 68% of VTGN (2026Q2)
- high13F: large increase
RENAISSANCE TECHNOLOGIES LLC added +151% to VTGN (2026Q2)
FREE, NO ACCOUNT
Every event on VTGN, as it fires
You are seeing 5 of 13 events recorded on VTGN since 2026-06-11.
The five above landed across 2 days. The other 8 were recorded on 3 other days. 8 of the 13 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VTGN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 92840H400 · 2026Q2 | $192K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 92840H400 · 2026Q2 | $165K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 92840H400 · 2026Q2 | $16K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VTGN
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VTGN against its peers
VTGN's operating margin of -5683.7% ranks in the 28th percentile of 8 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | VTGN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.3M USD | 568651 USD | 59 | 10 |
| Gross margin | n/a | 35.3% | n/a | 5 |
| Operating margin | -5683.7% | -550.2% | 28 | 8 |
| Net margin | -5491.3% | -433.7% | 25 | 9 |
| Return on equity | -196.2% | -125.9% | 31 | 17 |
Peers (21): CMMB, BOLT, MTVA, CURX, IMRN, CNSP, BCLI, OSRH, TCRT, PTN, XCUR, TPST, TOVX, LEXX, AIM, OTLC, APRE, CALC, VSBC, NIKI, CSCIF. Left out: CUBT (no annual filing), ADAPY (no annual filing), FBLG (no annual filing), ENVB (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (VTGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VTGN on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VTGN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.